Dosing and Administration

Avastin^© in combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Avastin^© dosing schedule

• 5 mg/kg of body weight given once every 14 days as an IV infusion
• In the Phase III clinical trial, Avastin^© was used until disease progression including instances in which modification of the chemotherapy regimen was required
• It is recommended that treatment be continued until progression of the underlying disease

Preparation for administration

• Avastin^© should be prepared using aseptic technique
• Withdraw the necessary amount of Avastin^© for a dose of 5 mg/kg of body weight and dilute in a total volume of 100 mL of sodium chloride 9 mg/mL (0.9%) solution for injection
• Discard any unused portion left in a vial, as the product contains no preservatives. Inspect visually for particulate matter and discolouration prior to administration
• Diluted Avastin^© solutions for infusion may be stored at 2°- 8°C for up to 24 hours
• Avastin^© infusions should not be administered or mixed with glucose solutions

Stability and storage

• Avastin^© vials must be refrigerated at 2°- 8°C. Keep the vial
• in the outer carton to protect from light. Do not freeze

Administration

• Avastin^© must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products
• Do not administer as an IV push or bolus

• The initial dose of Avastin^© should be given following chemotherapy. All subsequent doses can be given before or after chemotherapy
• Infusion reactions were rarely observed in clinical trials
• Dose reduction for adverse events is not recommended. If indicated, Avastin^© should either be discontinued or temporarily suspended